Major International Cannabis Study Designed—But No Results Yet
The “Blowing Minds” protocol aims to track recreational and medicinal cannabis users across multiple countries for two years using smartphone-based ecological momentary assessment, representing one of the most ambitious naturalistic cannabis research designs proposed to date, though it has not yet produced any empirical findings.
Why This Matters
Cannabis use is expanding globally under rapidly shifting legal frameworks, yet researchers still lack rigorous, real-world data on how regular use shapes mood, cognition, and mental health over time. Most existing studies rely on retrospective self-report, focus on a single jurisdiction, and treat cannabis users as a monolithic group. The gap between what patients and policymakers need to know and what the evidence actually supports remains wide. A well-designed international protocol that tracks both recreational and medicinal users in real time could meaningfully advance the field, but only if it is executed faithfully and interpreted with appropriate caution.
Clinical Summary
Cannabis research has long been hampered by methodological limitations including inconsistent exposure measurement, cross-sectional designs, and a near-exclusive focus on either harms or benefits depending on the investigators’ orientation. The Blowing Minds protocol, published in Comprehensive Psychiatry, describes a planned observational longitudinal study that addresses several of these shortcomings simultaneously. The design combines Experience Sampling Method (ESM), delivered via smartphone over 14 consecutive days, with traditional survey assessments at baseline, one year, and two years. ESM captures affect, craving, sleep quality, and cannabis use in near-real-time, reducing the recall bias that plagues conventional survey research. The study spans multiple legal jurisdictions including the Netherlands, the United States, Brazil, Canada, and sites in Asia and Africa, and it explicitly compares medicinal and recreational users aged 18 to 65.
Because this is a protocol paper, no data, results, or statistical analyses are presented. The authors frame the study as deliberately data-driven rather than hypothesis-driven, citing the polarized and inconsistent state of prior cannabis literature as justification for this approach. Primary outcomes of interest include affective states, cannabis craving patterns, cognitive function, and cannabis use disorder symptoms, moderated by jurisdiction, legal context, culture, and individual characteristics. Key limitations that cannot be assessed until the study is completed include recruitment success, retention across the two-year follow-up, and whether the self-selected sample will permit meaningful cross-group comparisons. The authors acknowledge that the non-random assignment to medicinal versus recreational use groups will preclude causal inference between those categories. No target sample size or formal power calculations appear in the published protocol text.
Dr. Caplan’s Take
This protocol addresses a real and frustrating gap in the evidence base. When patients ask me whether cannabis helps or harms their mental health, the honest answer is that we do not have the kind of longitudinal, ecologically valid, cross-cultural data we need to answer that question with confidence. A study designed to track real-time mood, craving, and cognition alongside two-year trajectories across multiple legal environments is exactly the kind of work the field needs. But I want to be clear: this paper describes a plan, not a result. It cannot tell us anything about what cannabis does to anyone.
In practice, when patients bring up studies like this, I use it as an opportunity to explain the difference between a promising research design and actionable evidence. I continue to approach cannabis recommendations on a case-by-case basis, weighing each patient’s clinical profile, current medications, and risk factors against the limited but growing evidence we do have. The Blowing Minds study may eventually provide valuable data, but until it does, the clinical conversation should not change based on its publication.
Clinical Perspective
This protocol sits at the very beginning of the research arc. It represents a pre-registration of intent and methodological transparency, not a contribution to the evidence base on cannabis effects. For clinicians, its value lies in signaling where the field is headed: toward real-time ecological assessment, cross-jurisdictional comparison, and explicit inclusion of medicinal users as a distinct population. None of these design features, however promising, alter what can currently be recommended to patients. The evidence supporting or refuting specific cannabis effects on mood, cognition, or sleep remains fragmented, and this protocol does nothing to resolve those uncertainties until data emerge.
Clinicians should be aware that patients may encounter media coverage of the Blowing Minds protocol and interpret it as evidence that cannabis effects are being “confirmed” or “studied internationally,” which can subtly inflate perceived legitimacy of unsubstantiated claims. No pharmacological, safety, or interaction conclusions can be drawn from a protocol paper. The single most actionable recommendation at this stage is to flag this study for future follow-up: when results are eventually published, they may provide the kind of naturalistic, longitudinal data that has been missing from clinical decision-making about cannabis use in psychiatric and general medical populations.
Study at a Glance
What Kind of Evidence Is This
This is a study protocol paper, which occupies a position near the base of the evidence hierarchy. Protocol papers describe the rationale, design, and planned methods for a future study. They carry no direct evidential weight about the phenomena under investigation. Their primary value is methodological transparency and, where formally registered, pre-specification of outcomes that reduces the risk of post-hoc analytical decisions. The single most important inference constraint is categorical: no claims about cannabis effects on mood, cognition, or mental health can be derived from this document.
How This Fits With the Broader Literature
The Blowing Minds protocol responds to well-documented limitations in the existing cannabis and mental health literature. Prior ESM studies, including work by Barkus and colleagues on cannabis and psychotic-like experiences and by Shrier and colleagues on real-time cannabis-mood associations in young adults, have demonstrated the feasibility and value of momentary ecological assessment in this domain. However, these studies have typically been small, short-term, and confined to single jurisdictions. The cross-cultural and multi-jurisdictional scope of this protocol is genuinely novel, as is the explicit plan to compare medicinal and recreational users longitudinally.
The protocol also reflects a broader methodological trend in substance use research toward ecological momentary assessment and away from sole reliance on retrospective surveys. Whether this particular study can deliver on its ambitious design will depend entirely on execution, and execution quality can only be evaluated once data are published.
Common Misreadings
The most likely misinterpretation of this paper is treating the protocol’s existence as evidence that the study’s hypothesized relationships have been confirmed or are being actively demonstrated. A protocol paper is a plan, not a finding. The fact that researchers intend to study whether cannabis affects mood and cognition across cultures does not mean they have shown it does so. Equally, the authors’ literature review sections, which cite prior ESM studies on cannabis-affect dynamics, should not be conflated with original findings from the Blowing Minds study itself. Citing this paper as evidence of cannabis effects would be a fundamental category error.
Bottom Line
The Blowing Minds protocol describes an ambitious, methodologically thoughtful plan to study cannabis effects on mental health and cognition across multiple countries using real-time ecological assessment and two-year follow-up. It fills no evidentiary gaps on its own because it presents no data. Its contribution is to the research infrastructure: signaling where the field is headed and what gaps future findings may address. Clinical practice should not change based on this publication, but clinicians should watch for the eventual results.
Frequently Asked Questions
Does this study prove that cannabis affects mental health?
No. This paper describes a research plan, not research results. No data were collected or analyzed as part of this publication. It outlines how scientists intend to study the relationship between cannabis use and mental health outcomes, but it provides no evidence about whether such a relationship exists or what form it takes.
Why would researchers publish a study design without results?
Publishing a protocol before data collection serves several purposes. It promotes methodological transparency, allows peer review of the design before results could bias interpretation, and establishes a public record of what the researchers planned to measure. This practice reduces the risk that analytical decisions will be made after the fact to favor particular conclusions, which is a well-documented problem in research.
What makes the Experience Sampling Method different from a regular survey?
Traditional surveys ask participants to recall their experiences over days, weeks, or months, which introduces significant memory distortion. ESM prompts participants multiple times per day via their smartphone to report what they are feeling, doing, or experiencing in near-real-time. This captures fluctuations in mood, craving, and behavior as they happen, providing a more granular and less biased picture of daily life than retrospective questionnaires can offer.
Will this study be able to prove that cannabis causes specific mental health outcomes?
Even when completed, this study will be observational rather than experimental. Participants are not randomly assigned to use or abstain from cannabis, so the design cannot establish causation. It can identify patterns, associations, and trajectories, and its real-time and longitudinal components strengthen its ability to describe temporal sequences, but confounding variables will remain a concern that only randomized controlled trials can fully address.
Should medicinal cannabis patients change anything based on this protocol?
No. Because this paper contains no findings, it provides no basis for changing any clinical decision. Patients currently using medicinal cannabis should continue to follow the guidance of their treating clinician. When the Blowing Minds study eventually publishes results, those findings can be evaluated on their own merits and may inform future recommendations, but that stage has not yet been reached.
References
- Blowing Minds Study Protocol. Comprehensive Psychiatry. Study protocol describing the design of a cross-cultural, longitudinal, ESM-based observational study of cannabis effects on mental health and cognition. DOI and PMID not provided in extracted data.
Have thoughts on this? Share it:
